Prostate Cancer - Results from #340

Immune effects of α and β radionuclides in metastatic prostate cancer. September 2, 2024

Challenges and Opportunities in Developing an Oncology Clinical Trial Network in the United States Veterans Affairs Health Care System: The VA STARPORT Experience. September 2, 2024

Diffusion MRI in prostate cancer with ultra-strong whole-body gradients. September 2, 2024

68Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with 18F-FDG. September 2, 2024

Associations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer. August 30, 2024

The 340B Program and High-Risk Prescribing of Oral Targeted Therapies for Advanced Prostate Cancer. August 30, 2024

Prostate Cancer Early Detection in the European Union and UK. August 30, 2024

Targeting PLOD2 suppresses invasion and metastatic potential in radiorecurrent prostate cancer. August 30, 2024

PARP inhibitors alone or in combination for prostate cancer. August 30, 2024

Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer: An Analysis of Real-World Practice Patterns from the CancerLinQ Database. August 29, 2024

RAD21 promotes oncogenesis and lethal progression of prostate cancer. August 29, 2024

Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate Cancer. August 29, 2024

5-α Reductase Inhibitors and Prostate Cancer Mortality. August 29, 2024

Mortality from prostate cancer in the years 2007-2021 in North Rhine-Westphalia, Germany. August 29, 2024

Appropriateness of Imaging for Low-Risk Prostate Cancer-Real World Data from the Pennsylvania Urologic Regional Collaboration (PURC). August 29, 2024

Prior Negative Biopsy, PSA Density, and Anatomic Location Impact Cancer Detection Rate of MRI-Targeted PI-RADS Index Lesions. August 29, 2024

Proton therapy toxicity outcomes for localized prostate cancer: Long-term results at a comprehensive cancer center. August 28, 2024

Barriers and facilitators of the application of precision medicine to the genitourinary cancer care pathway: Perspective from a low- and middle- income country in sub-Saharan Africa. August 28, 2024

The impact of neoadjuvant relugolix on multi-dimensional patient-reported fatigue. August 28, 2024

Cost-utility Analysis of Navigate, a Treatment Decision Aid for Men with Prostate Cancer and Their Partners, in Comparison to Usual Care. August 28, 2024

Page 18 of 1436